With CTLA-4 Antibody Deal, BioNTech Comes Face-to-Face with BMS’ Yervoy (March 21, 2023) | By Tristan Manalac. Monday, BioNTech inked an exclusive worldwide license and collaboration agreement with Maryland-based biopharma OncoC4 to develop and commercialize its investigational anti-CTLA-4 antibody ONC-392 for solid tumors. The partnership represents BioNTech’s return to its oncology roots. Though BioNTech is

CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery Programs Collaboration will leverage CHARM’s DragonFold deep learning platform to identify compounds against targets of interest (March 20, 2023) | By BUSINESS WIRE. LONDON–(BUSINESS WIRE) — CHARM Therapeutics (“CHARM”), a 3D deep learning biotechnology company discovering and developing transformational

Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. (March 15, 2023) | By JIM CORNALL. Seagen is a global biotechnology company that discovers, develops, and commercializes cancer medicines. The boards of

MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders-Seventure etc (February 17, 2023) | By Maat Pharma SA. MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders Lyon, France, February 17, 2023, 7:30 am CET – MaaT Pharma (EURONEXT: MAAT –

Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs (February 16, 2023) | By Katherine Lewin, News Reporter. Merck is betting on Aqilion’s work on a small molecule inhibitor for autoimmune and inflammatory diseases, including neurological diseases. Merck is paying €10 million upfront cash to the Swedish-based biotech in a licensing deal and research collaboration

Atomic AI Launches with $35 Million Series A Financing to Advance AI-driven RNA Structure Platform for Treating Undruggable Diseases (January 25, 2023) | By BUSINESS WIRE. SAN FRANCISCO — (BUSINESS WIRE) — Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, launched today with a $35

BIOHM Raises $7.5 Million to Accelerate Microbiome Research, Artificial Intelligence Capabilities and Product Development (January 12, 2023) | By BIOHM Health. The funding round, led by Middleland Capital’s VTC Ventures, will fast-track growth of A.I. technology and targeted, data-driven microbiome formulations CLEVELAND, Jan. 12, 2023 /PRNewswire/ — BIOHM, a leading microbiome company guided by the

Battelle, AmplifyBio, Andelyn team up NIH contract targeting stroke, neurological disease (January 10, 2023) | By Carrie Ghose – Staff reporter. A team comprising Battelle and two Central Ohio biotech startups has won a federal contract to supply the critical scientific and manufacturing support to bring regenerative medicine therapies for neurological disorders to market. Battelle

Enveda Biosciences Closes $68-million Combined Series B Equity and Debt Financing (December 21, 2022) BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences today announced that it has closed a $68-million equity and debt financing. Dimension led the Series B round, which included participation by multiple new institutional investors, including FPV, Jazz Venture Partners, Level Ventures, Amino Collective, Allen &

Wave Life Sciences to receive $170M upfront in new partnership with GSK to develop a large number of candidates (December 13, 2022) | By Tyler Patchen. Wave Life Sciences has picked up another deal with a major pharma company. The Massachusetts-based biotech on Tuesday announced it has entered a strategic collaboration with GSK to advance